Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00199433 · ClinicalTrials.gov registry record · Phase 2
A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
A Phase 2 study of Parkinson's Disease and Movement Disorder Syndrome, sponsored by Kyowa Kirin.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT00199433: Completed Phase 2 study of Parkinson's Disease and Movement Disorder Syndrome, sponsored by Kyowa Kirin.
NCT00199433 is a Phase 2 study of Parkinson's Disease and Movement Disorder Syndrome that has completed, run by Kyowa Kirin. The registered enrollment target is 160 participants, below the 634-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00199433, a Phase 2 study of Parkinson's Disease and Movement Disorder Syndrome, has completed, sponsored by Kyowa Kirin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) as monotherapy in patients with Parkinson's disease.
Conditions Studied
Interventions
- DRUG Istradefylline (KW-6002)
Study Locations (1)
New Jersey
- Kyowa Pharmaceutical Inc. - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
What the finished NCT00199433 record still lists
NCT00199433 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 634-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (75% lower).
The record links to 2 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Istradefylline (KW-6002) is the first listed.
NCT00199433 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00199433 about?
NCT00199433 is a clinical study titled "A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients". The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) as monotherapy in patients with Parkinson's disease.
What is the current status of trial NCT00199433?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2005-05. Estimated completion is 2006-08.
What conditions does trial NCT00199433 study?
This clinical trial studies the following conditions: Parkinson's Disease, Movement Disorder Syndrome.
What interventions are being tested in trial NCT00199433?
The interventions under investigation include: Istradefylline (KW-6002) (DRUG).
Who is sponsoring clinical trial NCT00199433?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00199433 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00199433's enrollment target sits among peer trials
160 42nd of 158 higher than 117 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RECRUITING · Phase 2
-
Tenapanor in Synucleinopathy-Related Constipation
RECRUITING · Phase 2
-
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia